NCT06493838View on ClinicalTrials.gov

Clinical Efficacy of Prophylactic Intravenous Neostigmine and Atropine in Preventing Post-Dural Puncture Headache Among Parturient Undergoing Spinal Anesthesia for Cesarean Section: A Double-blind Randomized Placebo-controlled Trial

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

July 15, 2024

Primary Completion Date

January 15, 2025

Study Completion Date

January 16, 2025

Conditions
Acute Pain
Interventions
DRUG

intravenous 50 mL of saline injection of 0.9% after umbilical cord clamping.

intravenous 50 mL of saline injection of 0.9% after umbilical cord clamping.

DRUG

Neostigmine 20μg/kg (Neostigmine Methylsulphate 0.5 mg, Amriya Pharm.Ind.) and atropine 0.01 mg/kg (diluted in 50 ml saline; 0.9% for 10 min) following umbilical cord clamping.

Neostigmine 20μg/kg (Neostigmine Methylsulphate 0.5 mg, Amriya Pharm.Ind.) and atropine 0.01 mg/kg (diluted in 50 ml saline; 0.9% for 10 min) following umbilical cord clamping.

All Listed Sponsors
lead

Minia University

OTHER

NCT06493838 - Clinical Efficacy of Prophylactic Intravenous Neostigmine and Atropine in Preventing Post-Dural Puncture Headache Among Parturient Undergoing Spinal Anesthesia for Cesarean Section: A Double-blind Randomized Placebo-controlled Trial | Biotech Hunter | Biotech Hunter